• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

    2/18/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email

    VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025.

    Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two decades, his experience in business development and capital deployment, together with his deep roots in the biotech and scientific communities, make him a valuable addition to the board of directors. Mr. Nodelman represents the seventh new director elected or appointed over the past two years as part of the company's board renewal process.

    Mr. Nodelman received a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University. He currently serves as a director of two other publicly-traded life science companies, Galapagos NV and AnaptysBio.

    "As the largest current stockholder of Zymeworks, we at EcoR1 are aligned with the company's mission and committed to its future success for patients, employees and stockholders," said Oleg Nodelman. "I look forward to working closely with the board of directors and talented employees as we execute on our long-term strategy to realize the full potential of Zymeworks."

    "We are pleased to welcome Oleg to Zymeworks' board of directors and believe his significant biotech sector experience will support our mission to develop transformative therapies for patients, while delivering lasting value to all our stockholders," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

    "Oleg's deep industry knowledge and experience make him an exceptional addition to the board of directors," said Sue Mahony, Ph.D., MBA, lead independent director of Zymeworks. "As part of our board renewal process, we are confident that Oleg's strategic insights will help drive the company's growth and reinforce our dedication to addressing critical medical challenges for patients."

    About Zymeworks Inc.

    Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the United States. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the potential therapeutic effects and commercial potential of zanidatamab and Zymeworks' other product candidates; the anticipated benefits of Zymeworks' agreements with Jazz Pharmaceuticals, BeiGene and its other collaborators; the commercial potential of zanidatamab and Zymeworks' and its partners' ability to obtain further regulatory approval of and successfully commercialize zanidatamab; the timing of and results of the interactions with regulators, including anticipated regulatory filings and the timing thereof; Zymeworks' development of its product candidates and enrollment in its clinical trials; the ability to advance product candidates into later stages of development; the timing of anticipated IND submissions; and other information that is not historical information. When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "progress", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab may not be successfully commercialized; clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; Zymeworks may be unable to maintain or enter into new partnerships or strategic collaborations; and the factors described under "Risk Factors" in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com).

    Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

    Contacts:

    Investor inquiries:

    Shrinal Inamdar

    Senior Director, Investor Relations

    (604) 678-1388

    [email protected]

    Media inquiries:

    Diana Papove

    Senior Director, Corporate Communications

    (604) 678-1388

    [email protected]



    Primary Logo

    Get the next $ZYME alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    11/1/2024$12.00Overweight → Equal Weight
    Wells Fargo
    3/21/2023$12.00Overweight
    Wells Fargo
    1/4/2023$10.00 → $8.00Neutral
    H.C. Wainwright
    12/20/2022$7.70 → $11.00Hold → Buy
    Jefferies
    11/1/2022$40.00 → $8.00Buy → Neutral
    H.C. Wainwright
    10/21/2022$8.00Outperform → Mkt Perform
    SVB Leerink
    More analyst ratings

    $ZYME
    Financials

    Live finance-specific insights

    See more
    • Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference call with management today at 4:30 p.m. Eastern Time (ET) VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to imp

      5/8/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. The event will be webcast live with dial-in details and webcast replay

      4/17/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAcceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC)Reported $324.2 million in cash resources as of December 31, 2024, which when combined with certain anticipated

      3/5/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 9:00:57 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 4:27:20 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zymeworks Inc.

      SC 13G - Zymeworks Inc. (0001937653) (Subject)

      11/13/24 4:30:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference call with management today at 4:30 p.m. Eastern Time (ET) VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to imp

      5/8/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

      Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the Americ

      4/25/25 1:00:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,497,322 worth of shares (127,415 units at $11.75) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/2/25 7:02:09 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    See more
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

      VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two de

      2/18/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO

      Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r

      8/6/24 7:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,497,322 worth of shares (127,415 units at $11.75) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/2/25 7:02:09 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    SEC Filings

    See more
    • SEC Form 10-Q filed by Zymeworks Inc.

      10-Q - Zymeworks Inc. (0001937653) (Filer)

      5/8/25 4:11:33 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zymeworks Inc. (0001937653) (Filer)

      5/8/25 4:08:55 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.

      SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)

      5/7/25 11:43:19 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zymeworks upgraded by Analyst with a new price target

      Analyst upgraded Zymeworks from Neutral to Overweight and set a new price target of $18.00

      12/16/24 6:40:30 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Zymeworks from Market Perform to Outperform and set a new price target of $25.00 from $10.00 previously

      11/7/24 6:47:25 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Zymeworks from Overweight to Equal Weight and set a new price target of $12.00

      11/1/24 7:40:43 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care